Next Quarterly Earnings
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Celltrion, a leading South Korean biopharmaceutical company, develops and manufactures innovative biosimilars and novel drugs. The company focuses on research and development to provide patient-centric therapies for global healthcare needs. Utilizing cutting-edge biotechnology, Celltrion enhances access to high-quality pharmaceutical solutions worldwide.
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Celltrion (068270) reported its Q3 2026 financial results on July 3, 2026, before market open. The company's earnings per share (EPS) came in at 1,351.86 KRW, which missed the analyst estimate of 1,450.51 KRW by 6.8%. Celltrion reported a revenue of 1,305,000 million KRW, and the stock price reacted with an increase of 3.96% after the release.
Generated automatically from our data — as of 07/12/2026 Read the article →
Celltrion is scheduled to report its next quarterly earnings on 11/05/2026. Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Celltrion last reported quarterly earnings on 7/3/2026 (Q2 2026). Earnings per share (EPS) came in at 1,623.12 KRW.
Across its last 4 earnings reports, Celltrion stock moved by ±2% on average the following day. The largest reaction was +4% on 07/03/2026; 3 of 4 reactions were positive.
Celltrion has beaten analyst EPS estimates in 4 of its last 4 evaluated quarters (beat rate: 100%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 4 report dates (close to close).
Basis: 4 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.